Related references
Note: Only part of the references are listed.Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Rena Wing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland
Wladyslaw Grzeszczak et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
M. J. Davies et al.
DIABETIC MEDICINE (2012)
Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes
Andre J. Scheen
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2012)
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
Ola Granstrom et al.
PRIMARY CARE DIABETES (2012)
Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
Scott Klarenbach et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents
William J. Valentine et al.
CLINICAL THERAPEUTICS (2011)
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
W. C. Lee et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
M. Brändle et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK
Amélie Beaudet et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España
Gordon Goodall et al.
Endocrinologia y Nutricion (2011)
Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes
Anushua Sinha et al.
DIABETES CARE (2010)
A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
P. McEwan et al.
DIABETES OBESITY & METABOLISM (2010)
A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
Jean-Eric Tarride et al.
PHARMACOECONOMICS (2010)
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
Maureen J. Lage et al.
ADVANCES IN THERAPY (2009)
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
T. Mittendorf et al.
DIABETES OBESITY & METABOLISM (2009)
Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
Anette Woehl et al.
CARDIOVASCULAR DIABETOLOGY (2008)
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy
B. Schwarz et al.
DIABETES OBESITY & METABOLISM (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
Joshua A. Ray et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions
E Adang et al.
HEALTH POLICY (2005)
Use of cost-effectiveness analysis in health-care resource allocation decision-making:: How are cost-effectiveness thresholds expected to emerge?
HG Eichler et al.
VALUE IN HEALTH (2004)
Share Paper
